Improvement and extension of anti-EGFR targeting in breast cancer therapy by integration with the Avidin-Nucleic-Acid-Nano-Assemblies
The nature of the linker is known to affect the efficacy of antibody–drug conjugate (ADC). Here the authors show cetuximab-guided Avidin-Nucleic-Acid-Nanoassemblies to be superior to cetuximab-doxorubicin conjugate, and show its efficacy in KRAS mutant breast cancer, allowing for therapeutic expansi...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2018-10-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-018-06602-6 |
| id |
doaj-5b9f1af1b8e049f592c27421c329d673 |
|---|---|
| record_format |
Article |
| spelling |
doaj-5b9f1af1b8e049f592c27421c329d6732021-05-11T09:51:19ZengNature Publishing GroupNature Communications2041-17232018-10-019111110.1038/s41467-018-06602-6Improvement and extension of anti-EGFR targeting in breast cancer therapy by integration with the Avidin-Nucleic-Acid-Nano-AssembliesFrancesco Roncato0Fatlum Rruga1Elena Porcù2Elisabetta Casarin3Roberto Ronca4Federica Maccarinelli5Nicola Realdon6Giuseppe Basso7Ronen Alon8Giampietro Viola9Margherita Morpurgo10Dipartimento di Scienze del Farmaco, Università di PadovaDipartimento di Scienze del Farmaco, Università di PadovaDipartimento di Salute della Donna e del Bambino, Università di PadovaANANAS nanotech, S.r.l.Department of Molecular and Translational medicine, University of BresciaDepartment of Molecular and Translational medicine, University of BresciaDipartimento di Scienze del Farmaco, Università di PadovaDipartimento di Salute della Donna e del Bambino, Università di PadovaDepartment of Immunology, The Weizmann Institute of ScienceDipartimento di Salute della Donna e del Bambino, Università di PadovaDipartimento di Scienze del Farmaco, Università di PadovaThe nature of the linker is known to affect the efficacy of antibody–drug conjugate (ADC). Here the authors show cetuximab-guided Avidin-Nucleic-Acid-Nanoassemblies to be superior to cetuximab-doxorubicin conjugate, and show its efficacy in KRAS mutant breast cancer, allowing for therapeutic expansion of anti-EGFR therapy.https://doi.org/10.1038/s41467-018-06602-6 |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Francesco Roncato Fatlum Rruga Elena Porcù Elisabetta Casarin Roberto Ronca Federica Maccarinelli Nicola Realdon Giuseppe Basso Ronen Alon Giampietro Viola Margherita Morpurgo |
| spellingShingle |
Francesco Roncato Fatlum Rruga Elena Porcù Elisabetta Casarin Roberto Ronca Federica Maccarinelli Nicola Realdon Giuseppe Basso Ronen Alon Giampietro Viola Margherita Morpurgo Improvement and extension of anti-EGFR targeting in breast cancer therapy by integration with the Avidin-Nucleic-Acid-Nano-Assemblies Nature Communications |
| author_facet |
Francesco Roncato Fatlum Rruga Elena Porcù Elisabetta Casarin Roberto Ronca Federica Maccarinelli Nicola Realdon Giuseppe Basso Ronen Alon Giampietro Viola Margherita Morpurgo |
| author_sort |
Francesco Roncato |
| title |
Improvement and extension of anti-EGFR targeting in breast cancer therapy by integration with the Avidin-Nucleic-Acid-Nano-Assemblies |
| title_short |
Improvement and extension of anti-EGFR targeting in breast cancer therapy by integration with the Avidin-Nucleic-Acid-Nano-Assemblies |
| title_full |
Improvement and extension of anti-EGFR targeting in breast cancer therapy by integration with the Avidin-Nucleic-Acid-Nano-Assemblies |
| title_fullStr |
Improvement and extension of anti-EGFR targeting in breast cancer therapy by integration with the Avidin-Nucleic-Acid-Nano-Assemblies |
| title_full_unstemmed |
Improvement and extension of anti-EGFR targeting in breast cancer therapy by integration with the Avidin-Nucleic-Acid-Nano-Assemblies |
| title_sort |
improvement and extension of anti-egfr targeting in breast cancer therapy by integration with the avidin-nucleic-acid-nano-assemblies |
| publisher |
Nature Publishing Group |
| series |
Nature Communications |
| issn |
2041-1723 |
| publishDate |
2018-10-01 |
| description |
The nature of the linker is known to affect the efficacy of antibody–drug conjugate (ADC). Here the authors show cetuximab-guided Avidin-Nucleic-Acid-Nanoassemblies to be superior to cetuximab-doxorubicin conjugate, and show its efficacy in KRAS mutant breast cancer, allowing for therapeutic expansion of anti-EGFR therapy. |
| url |
https://doi.org/10.1038/s41467-018-06602-6 |
| work_keys_str_mv |
AT francescoroncato improvementandextensionofantiegfrtargetinginbreastcancertherapybyintegrationwiththeavidinnucleicacidnanoassemblies AT fatlumrruga improvementandextensionofantiegfrtargetinginbreastcancertherapybyintegrationwiththeavidinnucleicacidnanoassemblies AT elenaporcu improvementandextensionofantiegfrtargetinginbreastcancertherapybyintegrationwiththeavidinnucleicacidnanoassemblies AT elisabettacasarin improvementandextensionofantiegfrtargetinginbreastcancertherapybyintegrationwiththeavidinnucleicacidnanoassemblies AT robertoronca improvementandextensionofantiegfrtargetinginbreastcancertherapybyintegrationwiththeavidinnucleicacidnanoassemblies AT federicamaccarinelli improvementandextensionofantiegfrtargetinginbreastcancertherapybyintegrationwiththeavidinnucleicacidnanoassemblies AT nicolarealdon improvementandextensionofantiegfrtargetinginbreastcancertherapybyintegrationwiththeavidinnucleicacidnanoassemblies AT giuseppebasso improvementandextensionofantiegfrtargetinginbreastcancertherapybyintegrationwiththeavidinnucleicacidnanoassemblies AT ronenalon improvementandextensionofantiegfrtargetinginbreastcancertherapybyintegrationwiththeavidinnucleicacidnanoassemblies AT giampietroviola improvementandextensionofantiegfrtargetinginbreastcancertherapybyintegrationwiththeavidinnucleicacidnanoassemblies AT margheritamorpurgo improvementandextensionofantiegfrtargetinginbreastcancertherapybyintegrationwiththeavidinnucleicacidnanoassemblies |
| _version_ |
1721449054372626432 |